Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione-4,5,6,7-d4
Purity: ≥99% deuterated forms (d1-d4)
Formula Markup: C13H6D4N2O4
Formula Weight: 262.25382
CAS Number: 1219177-18-0
Notes: (±)-Thalidomide-d4 is intended for use as an internal standard for the quantification of (±)-thalidomide (Item No. 14610) by GC- or LC-MS. (±)-Thalidomide is an immunomodulatory compound with diverse biological activities, including anticancer, anti-inflammatory, and teratogenic properties.{54394,54393,54392} It prevents polymorphonuclear leukocyte (PMN) chemotaxis when used at concentrations of 1, 10, and 100 µg/ml.{54394} (±)-Thalidomide increases IL-2-induced proliferation and IFN-γ production in primary human T cells in vitro.{54393} It enhances natural killer (NK) cell-mediated cytotoxicity in MM.1S multiple myeloma cells.{54392} Thalidomide (4 mg/animal) reduces lung IL-6, TGF-β, VEGF, angiopoietin-1, angiopoietin-2, and collagen type Iα1 expression, inhibits pulmonary angiogenesis, and attenuates fibrosis in a mouse model of bleomycin-induced pulmonary fibrosis.{54395} It induces apoptosis in primary human embryonic fibroblasts (EC50 = 8.9 µM) and induces limb and eye defects in chicken embryos (EC50 = 50 µg/kg egg weight).{54396} Formulations containing thalidomide have been used in the treatment of multiple myeloma and erythema nodosum leprosum (ENL) in non-pregnant individuals.
English
Deutsch
